Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 6/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23355478 | 0.84 | MAPT (0.34) | BACE1BACE2ATRCA1CA2 | |
| SCHEMBL23355350 | 0.82 | MAPK14 (0.35) | KDM4EMAPTNPC1ALDH1A1GAA | |
| SCHEMBL24037618 | 0.80 | PIM1 (0.32) | LRRK2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29834653 | 0.79 | PIM1 (0.32) | LRRK2ALDH1A1 | |
| SCHEMBL23355355 | 0.79 | LRRK2 (0.32) | LRRK2 | |
| SCHEMBL21612849 | 0.78 | MAPT (0.33) | BACE1BACE2ATRMAPT | |
| SCHEMBL21612850 | 0.78 | MAPT (0.33) | BACE1BACE2ATRMAPTGPR119 | |
| SCHEMBL24926751 | 0.78 | BRAF (0.40) | MAPT | |
| SCHEMBL29834678 | 0.77 | CDC25A (0.35) | KDM4EMAPTNPC1ALDH1A1RAB9A | |
| SCHEMBL23368034 | 0.76 | KDM4E (0.50) | BACE1BACE2ATRKDM4ELRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025510-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025510-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES | ERBB2, EGFR, ERBB3 | BACE1 3888/4885BACE2 2699/4885ATR 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.